Background Previous studies suggest that Dupuytren's disease is caused by fibroblast and myofibroblast contractility. Cell contractility in smooth muscle cells is caused by calcium-dependent and calcium-independent signaling mechanisms. In the calcium-dependent pathway, calcium/ calmodulin activates myosin light chain kinase (MLCK). In this study, the effects of calcium/calmodulin inhibition with the FDA-approved drug fluphenazine on Dupuytren's fibroblast contractility and MLCK expression were tested. Methods Fibroblast lines from the palmar fascia of patients with Dupuytren's disease were explanted and used for in vitro study. The effect of fluphenazine on Dupuytren's fibroblast migration was determined using a scratch migration assay, and contractility was determined using fibroblast-populated collagen lattice (FPCL) assays. Immunohistochemical staining of MLCK in different samples of Dupuytren's tissue and normal fascia were compared.
Results Fluphenazine demonstrated a dose-dependent inhibition of Dupuytren's fibroblast migration, with the maximum inhibition of migration observed at 20 μM (69.8±1.9%). Fluphenazine also inhibited FPCL contraction in a dosedependent manner. Maximal inhibition was observed at a fluphenazine concentration of 20 μM (52.5±6.1%). Immunohistological staining illustrated that MLCK was predominantly expressed throughout the cytoplasm of select fibroblasts within Dupuytren's nodules, yet was absent in the fibroblasts of Dupuytren's cords and normal palmar fascia. Conclusions Fluphenazine inhibits Dupuytren's fibroblast contractility and migration through inhibition of MLCK in vitro. However, the inconsistent expression of MLCK throughout Dupuytren's tissue suggests that calciumdependent signaling may not be a primary mode of contracture formation. Fluphenazine inhibition of MLCK is not likely to be a target for the treatment of Dupuytren's disease.
Keywords Calcium-dependent signaling Dupuytren's disease is an idiopathic, prevalent fibrocontractile disease that can be severely debilitating to hand function. Diseased fascia contains nodules that are believed to be the primary epicenter of disease progression because they frequently precede cord formation and contain highly contractile myofibroblasts [33] . Increased fibroblast and myofibroblast migration and contractility were thought to cause Dupuytren's disease. Fibroblast and myofibroblast migration and contraction result from a complicated series of interacting of pathways resulting in the phosphorylation of myosin light chain [21] . Myofibroblasts and fibroblasts are rich in actin and myosin contractile proteins, which are activated by upstream signaling kinases such as calciumindependent Rho associated kinase and calcium-dependent myosin light chain kinase (MLCK) [5] . It is possible that the increased expression or activity of these signaling kinases could play a role in Dupuytren's contracture. The role of MLCK in Dupuytren's disease has not been investigated.
MLCK is activated by increases in intracellular calcium. Intracellular calcium is increased by extracellular stimuli that promote release from intracellular stores and influx from the extracellular space. Intracellular calcium binds to calmodulin which in turn activates MLCK, resulting in the phosphorylation of the regulatory myosin light chain (MRLC) peptide on myosin II [11, 20, 31, 37] . The increase in MRLC activity produces actin-myosin contraction and, in dermal fibroblasts and smooth muscle cells, increased migration and collagen contraction. This calcium-calmodulin-dependent MLCK activity has not been investigated in Dupuytren's fibroblast activity.
Calmodulin-dependent MLCK activity is inhibited by the Food and Drug Administration (FDA)-approved phenothiazine derivatives, such as fluphenazine [24] [25] [26] 43] . In this study, we determined if MLCK is capable of inducing Dupuytren's fibroblast activity by inhibiting calmodulindependent MLCK function with fluphenazine and assessed the effect on cell contraction and migration in vitro. This data could suggest calmodulin-dependent MLCK inhibition with fluphenazine is a potential target for preventing Dupuytren's disease. Current treatments are marginally effective and there is a need to discover novel and better therapeutics. By providing new insights into the molecular mechanisms into signaling pathways of Dupuytren's fibroblast activity, more focused Dupuytren treatments can be developed.
Materials and Methods

Human Tissue and Fibroblast Explantation
All tissues were obtained in accordance with the Duke University Medical Center Institutional Review Board. Formalin-embedded Dupuytren tissues for immunohistological staining were obtained from the Duke University Medical Center, Department of Pathology repository of tissue specimens; normal cadaveric palmar fascia was obtained from the Duke Human Fresh Tissue Laboratory and used for immunohistological staining. Dupuytren fibroblasts were explanted from patients undergoing surgical fasciectomy. Dupuytren's nodules were then dissected from the surrounding cords and palmar fascia. In brief, the tissue samples were washed, finely minced, and incubated in collagenase type I in Hank's balanced salt solution with 1% penicillin/streptomycin at 37°C for 4 h. The cells were subsequently cultured in Dulbecco's modified Eagle's medium (DMEM; Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (Invitrogen, Carlsbad, CA). Cells were maintained in a 37°C incubator with 5% CO 2 . Experiments with primary cell cultures were performed when cells were 80-90% confluent between passages 1 and 6. For in vitro experiments, four cell strains from different patients were used.
Immunohistochemical Staining
Consecutive sections of 5 μm for each tissue specimen were mounted on silanized charged slides and allowed to dry for 30 min in an incubator at 60°C. After deparaffinization in xylene and rehydration, slides were covered for 10 min with 3% hydrogen peroxide to block endogenous peroxidase. Slides were then placed in citrate antigen retrieval buffer for 20 min at 100°C, followed by washing in Tris-buffered saline Polysorbate-20 (TBST), 0.5 M Tris Base, 9% NaCl, 0.5% Polysorbate-20 (pH 8.4) at room temperature. Slides were then placed in a humidified chamber and incubated for 45 min with mouse anti-MLCK at 1:500 dilution (Clone K36, Sigma-Aldrich. St. Louis, MO). After three rinses in TBST, the slides were incubated for 45 min with biotinylated secondary detection antibodies (horse anti-mouse at 1:200 dilution, Vector, Burlingame, CA). After three rinses in TBST, the slides were incubated with the detection system (Vectastain Elite ABC, Vector Laboratories, Inc., Burlingame, CA) for 30 min. Tissue staining was visualized with a 3,3'-diaminobenzidine substrate chromogen solution (Dako, Carpinteria, CA). Nonimmune controls were performed by using a mouse IgG at matched concentration. Sections were analyzed with the assistance by a dermatopathologist.
Scratch Migration Assay
Fibroblasts were added to a 24-well plate at 4.5×10 4 cells per milliliter and allowed to adhere for at least 8 h. The media was drawn off and the wells were scratched with a P-20 pipette tip. The wells were washed with PBS to remove any non-adherent cells. A mark across the bottom of the well, to be used as a reference point, was made perpendicular to the scratch before the cells were added. Fluphenazine (0.63-20 μM in growth media) (Sigma-Aldrich, St. Louis, MO), growth media or DMEM alone was added to the wells. Migration was measured by capturing an image of each well at the reference point at 0, 11, 15, and 19 h. The images were analyzed with ImageJ (NIH, Bethesda, MD) software. All data were repeated for four cell strains in triplicate.
Fibroblast-Populated Collagen Lattices
Fibroblast-populated collagen lattices (FPCL) were made as follows: 400 μL of fibroblast-collagen-medium mixture at concentration of 1.0×10 5 cells per milliliter, 1.28 mg/mL purified collagen (Nutragen, Advanced Biomatrix, Fremont, CA, USA) was added into a 24-well flat bottom tissue culture plate that had been blocked with bovine serum albumin (BSA). The plate was placed in a 37°C incubator with 5% CO 2 for 60 min to allow the collagen to polymerize, before adding 500 μL of 0.5% BSA in DMEM, media or fluphenazine in media (0.63-20 μM). FPCL were freed from the surface of the wells. The sizes of lattices were recorded using a digital scanner at 2, 8, and 10 h. The areas of each lattice were determined and measured using the ImageJ (NIH, Bethesda, MD) software. All conditions were performed in triplicate per experiment, for four cell strains.
Statistical Analysis
All values are presented as mean±standard error of mean. Statistical analysis was performed using JMP software (SAS Institute version 7, Cary, NC). Differences between groups were compared via Student's t test and were considered statistically significant at values of p≤0.05.
Results
Immunohistochemical Staining of Dupuytren's Disease and Normal Palmar Fascia
Routine histologic sections of Dupuytren's nodules and cords from four different patients and normal palmar fascia from four different cadavers were stained for MLCK expression. Low-power magnification reveals expression of MLCK in Dupuytren's nodules but little to absent expression of MLCK within Dupuytren's cords and normal palmar fascia (Fig. 1) . High-power magnification of the same specimens demonstrates predominant expression of MLCK in the cytoplasm of nodule fibroblasts. Immunohistological staining of the Duputryen tissue indicates that MLCK is more robustly expressed and widely distributed throughout the cytoplasm of Dupuytren's nodule fibroblasts as compared to the scant perinuclear localization seen within Dupuytren's cords fibroblasts and normal palmar fascia fibroblasts.
Effects of Fluphenazine on Fibroblast Activity
Fibroblasts were explanted from tissue excised from four separate patients undergoing surgery for Dupuytren's contracture. The effect of fluphenazine on Dupuytren's fibroblast migration was examined using a scratch assay. In the cell scratch assay, migration was stimulated by FBS; this was the maximum migration rate observed. Both the effect of concentration and exposure time to fluphenazine were evaluated. Fluphenazine demonstrated a dosedependent inhibition of Dupuytren's fibroblast migration. The maximum inhibition of migration was observed at 20 μM, the highest concentration of fluphenazine assayed, with 69.8±1.9% of Dupuytren's fibroblasts having not migrated (Fig. 2a,b) . Fluphenazine inhibited migration compared to FBS that stimulated migration after 11 h. After 15 h, migration of Dupuytren's fibroblasts was only inhibited by 20 μM of fluphenazine as compared to the control.
MLCK-Promoted FPCL Contraction was Blocked by Fluphenazine
Dupuytren's fibroblast was cultured in 3D free-floating FPCLs and contraction measured. Data is reported as a percent of area of the original size of the FPCL, i.e., the smaller the percentage in area the smaller the FPCL and the greater the contraction. Dupuytren's fibroblasts were highly contractile, with the FBS-stimulated contraction decreasing the area of FPCL to 13.7±0.3% after 8 h. Fluphenazine inhibited FPCL contraction in a dose-dependent manner, and a concentration of greater than 2.5 μM was required to significantly inhibit Dupuytren's FPCL contraction (p≤ 
Discussion
Dupuytren's disease is an idiopathic, prevalent fibrocontractile disease of the palmar fascia that can be severely debilitating to hand function. There are several comorbid conditions which suggest an increased predisposition for Dupuytren's disease formation, including male gender, increased age, Northern European descent, history of smoking, repetitive trauma to the hands, family history, diabetes, and seizures [4, 6, 13-19, 27, 32, 34, 45] .
Diseased palmar fascia contains nodules and cords and although it is unknown why these structures develop, it has been proposed that nodules are the primary epicenter of disease progression because they frequently precede cord formation and contain highly contractile myofibroblasts [33] . While some investigators believe that myofibroblasts are putatively responsible for causing Dupuytren's disease progression, it is interesting to note that not all nodules contain myofibroblasts [9] . Although the pathogenesis of Dupuytren's disease is unknown, it does share similarities to scar contracture [9, 41] . Both occur incrementally as a result of fibroblast and myofibroblast contractility [7, 38] .
Actomyosin-based cell contractility throughout the human body has been well studied and the findings may be relevant to Dupuytren's disease [28, 39] . It is uncertain exactly whether myofibroblasts are regulated in a manner similar to that of fibroblasts or to smooth muscle cells, as alpha smooth muscle actin is expressed in stress fibers of differentiated Fig. 2 Inhibition of migration of Dupuytren's fibroblasts by fluphenazine. Fibroblasts were explanted from Dupuytren's tissue and cultured in 24-well plates, following which a scratch was made and fluphenazine was added to the medium at 0-20 μM. Migration of Dupuytren's fibroblasts were measure by taking images at 15 h then measuring the unmigrated area using ImageJ; data is reported as migration rate in percent. a Maximum migration rate was observed in DMEM+FBS and the minimum migration rate was observed in DMEM-FBS Dupuytren's fibroblast migration was inhibited by fluphenazine in a dose-dependent manner. b The effect of fluphenazine concentration on Dupuytren's fibroblast migration over 20 h DMEM-FBS (ex mark), DMEM+FBS (plus sign), 20 μM (black triangle), 10 μM (black diamond), 2.5 μM (black square). Data is presented as mean±standard error Fig. 3 The effect of fluphenazine on contraction of Dupuytren's fibroblast-populated collagen lattices. Dupuytren's fibroblast was cultured within 3D collagen lattices, contraction of free-floating FPCL was measured by taking images at a 8 h and analysis of the area of the FPCL with ImageJ. Fluphenazine inhibited Dupuytren's FPCL contraction. b The effect of fluphenazine concentration on Dupuytren's FPCL contraction over 20 h, DMEM+FBS (+), 20 μM (triangle), 10 μM (black diamond), 2.5 μM (black square). Data is presented as mean±standard error myofibroblasts [7] . There are two systems which appear to regulate the phosphorylation of MRLC, which in turn regulates the contractile stress fibers of myofibroblasts: the calcium-dependent calmodulin-MLCK pathway and the calcium-independent Rho-kinase pathway [5] . It has been demonstrated that the Rho-kinase pathway is the predominant regulatory pathway for myofibroblast contraction [3, 29] . However, little is known regarding the relative contribution of each regulatory pathway to myofibroblast contractility in pathophysiologic states, such as Dupuytren's disease [10] . It is important to elucidate which regulatory pathway of myofibroblast contractility predominates in Dupuytren's disease, as there are currently several FDAapproved drugs that block each pathway [22, 23, 30, 42] .
Both regulatory pathways work by activating MRLC. This is done by either directly phosphorylating MRLC at seronine or threonine residues or indirectly by phosphorylating and deactivating the regulatory subunit of MRLC phosphatase [35, 36] . Activated MRLC, in turn, extends the neck domain of the cytoskeletal protein non-muscle myosin II (NMMII). This facilitates actin binding (β-actin in fibroblasts and α-smooth muscle actin and β-actin in myofibroblasts) at the NMMII N-terminal motor domain, thereby conferring ATPase activity. This interaction of β-, γ-, or α-smooth muscle actin with NMMII is believed to mediate cell force generation in Dupuytren's fibroblasts [40] . Importantly, NMMII is believed to be the final common effector protein of all contractile agonists and is therefore hypothesized to be the key regulator of scar contractures and wound contraction. What remains unclear is which of the upstream agonists is most critical in prevention of NMMII expression and subsequent matrix contraction.
When intracellular concentrations of calcium increase, the calcium binds to calmodulin which in turn binds to and activates MLCK [11, 20, 31, 37] . MLCK activity is inhibited by the phenothiazine derivatives class of drugs, commonly used in the treatment of psychosis [24] [25] [26] 43] . Inhibition of calcium-dependent myosin light chain peptide phosphorylation has been shown in smooth muscle cells by these agents [44] . Fluphenazine is a member of the phenothiazine class of drugs. It is thought that fluphenazine works by directly binding to the calmodulin-calcium complex, resulting in inhibition of myosin P-light chain phosphorylation [43] . Fluphenazine is used in the treatment of multifocal tic disorders and other psychotic conditions and it is well tolerated [1, 2, 8, 12] . We, therefore, reasoned that its use would be safe in the possible treatment of Dupuytren's disease. We proposed that inhibition of MLCK with fluphenazine would result in reduced fibroblast contractility by blocking the upstream signaling pathway.
Our data shows that fluphenazine inhibits the migration of Dupuytren's fibroblasts in a dose-dependent manner. The greatest amount of inhibition occurred at the highest concentration tested. This most likely is a result of greater saturation of calmodulin receptors at higher doses of fluphenazine. When we looked at the effect of time on fibroblast migration, there was no significant difference noted in the migration of fibroblasts within the first 10 h. After 10 h, however, there was a difference in the amount of cell migration noted. Our studies with unstressed FPCL show that MLCK-mediated fibroblast contractility is mitigated by fluphenazine in a dose-dependent manner, with the maximum inhibition of percentage decrease in Dupuytren's FPCL area observed at the highest concentration of fluphenazine tested. A fluphenazine concentration of greater that 2.5 μM was required to significantly inhibit Dupuytren's FPCL contraction. Immunohistochemical staining of Dupuytren's tissue revealed robust expression of MLCK in Dupuytren's nodules but little to absent expression of MLCK within Dupuytren's cords and normal palmar fascia. This indicates that in Dupuytren's tissue, MLCK is focally located within nodules, but scant overall. From these immunohistochemical findings, it is possible that the calcium-dependent pathway of MLCK activation is not centrally important to progression of Dupuytren's disease. As there are no animal models of Dupuytren's disease, it is difficult to test progression of the disease in vivo.
Scientific discovery of the signaling mechanisms of Dupuytren's contracture formation is the key to developing novel interventions to prevent disease progression. Dupuytren's disease is a slowly progressive fibrocontractile process, and the mechanism of contraction is believed to be similar to those that cause scar contractures. Our data support the notion that MLCK activation may play a small role in disease progression but is unlikely to have a major impact. Future research should look at the role of calcium-independent pathways, such as with Rho-kinase, in disease progression. The longterm goal is to identify the proteins that cause fascia contraction and their location, so that new agonist/ antagonistic drugs can be developed or an existing drug can be modified for use in the clinic.
Conclusion
In summary, fluphenazine inhibits Dupuytren's fibroblast contractility and migration through inhibition of MLCK in vitro. The inconsistent expression of MLCK throughout Dupuytren's nodules suggests that contractures may develop from calcium-independent signaling. Fluphenazine inhibition of MLCK alone is not likely to be a target for the treatment of Dupuytren's disease due to inconsistent expression.
